Development of anaphylactic shock in haemophilia B patients with inhibitors

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Warrier, I ^a   Lusher, J M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Anaphylaxis; Genotyping; Haemophilia B; Immune tolerance induction; Inhibitor antibodies; Nephrotic syndrome; Recombinant FVIIa

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 9; GENE PRODUCT; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANAPHYLACTIC SHOCK; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE CONTROL; FRAMESHIFT MUTATION; GENE ACTIVITY; GENE DELETION; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INCIDENCE; PATIENT MONITORING; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RISK FACTOR;

ANAPHYLAXIS; ANTIBODIES; FACTOR IX; GENOTYPE; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; NEPHROTIC SYNDROME; RECOMBINANT PROTEINS;

EID: 0031727621     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Briët E. Factor IX inhibitor in hemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coag Fibrinol 1991; 2 (suppl 1):47-50.
2. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94 (suppl 1):49-52.
3. Giannelli F, Green PM, Sommer SS, Lillicrap DF, Ludwig M, Schwaab R, et al. Haemophilia B: database of point mutations and short additions and deletions. Fifth edition, 1994. Nucleic Acids Res 1994; 22:3534-3546.
4. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, et al. FIX inhibitor and anaphylaxis in haemophilia B [correspondence]. Haemophilia 1996; 2:259-261.
5. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, et al. Factor IX inhibitors and anaphylaxis in haemophilia B. J Pediatr Hematol Oncol 1997; 19:23-27.
6. Schafer AI. Coagulation cascade: an overview. In: Thrombosis and Hemorrhage. Loscalzo J, Schafer AI (editors). Cambridge, UK: Blackwell Scientific Publishers, Inc.; 1994. pp. 3-12.
7. Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54:201-213.
8. Sawamoto Y, Shima M, Yamamoto M, Kamisue S, Nakai H, Tanaka I, et al. Measurement of anti-FIX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res 1996; 83:279-286.
9. Bergmann F, Vester U, Rose M, Hoyer PF, Bohn U, Barthels M. Behandlungsaltervativen bei Hemmokörperhämophilie B: Erfahrungen mit dem Einsatz von rekombinatem Faktor VIIa (rFVIIa). In: Hämophilie-symposium Hamburg, Berlin. Scharrer I, Schramm W (editors) Heidelberg: Springer-Verlag; 1994. pp. 126-129.
10. Ewenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89:115-116.
11. Lenk H, Bierback U, Schille R. Inhibitor to FIX in haemophilia B and nephrotic syndrome in the course of immune tolerance treatment [abstract]. Haemophilia 1996; 2 (suppl 1):104.
12. Pollmann H. A haemophilia B patient with complete factor IX gene deletion and a high titre antibody against FIX [abstract]. Haemophilia 1996; 2 (suppl 1):72.